IGF/IGFBP axis in cartilage and bone in osteoarthritis pathogenesis

Inflammation Research

Volumn 47, Issue 3, 1998, Pages 90-100

  Martel Pelletier, J ^a   Di Battista, J A ^a   Lajeunesse, D ^a   Pelletier, J P ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Cartilage bone; IGF 1; IGFBP; Osteoarthritis

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN C;

BONE; CARTILAGE; CARTILAGE CELL; HUMAN; OSTEOARTHRITIS; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW;

BONE AND BONES; CARTILAGE; CHONDROCYTES; CYTOKINES; HOMEOSTASIS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; OSTEOARTHRITIS; PROMOTER REGIONS (GENETICS); RNA, MESSENGER;

EID: 0031918202     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000110050288     Document Type: Review

References (135)

1. Pelletier JP, Martel-Pelletier J, Howell DS. Etiopathogenesis of osteoarthritis. In: Koopman WJ, editor. Arthritis and Allied Conditions. A Textbook of Rheumatology. 13th ed. Baltimore: Williams & Wilkins, 1997:1969-84.
2. Pelletier JP, Roughley PJ, Di Battista JA, McCollum R, Martel-Pelletier J. Are cytokines involved in osteoarthritic pathophysiology? Semin Arthritis Rheum 1991;20:12-5.
3. Dean DD. Proteinase-mediated cartilage degradation in osteoarthritis [review]. Semin Arthritis Rheum 1991;20:2-11.
4. Mitchell N, Shepard N. Pericellular proteoglycan concentrations in early degenerative arthritis. Arthritis Rheum 1981;24:958-64.
5. Mankin HJ, Lippiello L. The glycosaminoglycans of normal and arthritic cartilage. J Clin Invest 1971;50:1712-9.
6. Vignon E, Arlot M, Hartmann D, Moyen B, Ville G. Hypertrophic repair of articular cartilage in experimental osteoarthritis. Ann Rheum Dis 1983;42:82-8.
7. Pelletier JP, Di Battista JA, Roughley PJ, McCollum R, Martel-Pelletier J. Cytokines and inflammation in cartilage degradation. In: Moskowitz RW, editor. Osteoarthritis. Edition of Rheumatic Disease Clinics of North America. Philadelphia: W.B. Saunders, 1993:545-68.
8. Haraoui B, Pelletier JP, Cloutier JM, Faure MP, Martel-Pelletier J. Synovial membrane histology and immunopathology in rheumatoid arthritis and osteoarthritis. In vivo effects of anti-rheumatic drugs. Arthritis Rheum 1991;34:153-63.
9. Guenther HL, Guenther HE, Froesch ER, Fleisch H. Effect of insulin-like growth factor on collagen and glycosaminoglycan synthesis by rabbit articular chondroytes in culture. Experientia 1982;38:979-81.
10. McQuillan DJ, Handley CJ, Campbell MA, Bolis S, Milway VE, Herington AC. Stimulation of proteoglycan biosynthesis by serum and insulin-like growth factor-I in cultured bovine articular cartilage. Biochem J 1986;240:423-30.
11. Franchimont P, Bassler C. Effects of hormones and local growth factors on articular chondrocyte metabolism. J Rheumatol 1991;18(Suppl 27):68-70.
12. Sandell LJ, Dudek EJ. Insulin-like growth factor I stimulates type II collagen gene expression in cultured chondrocytes. Trans Orthop Res Soc 1988;35:300.
13. Tesch GH, Handley CJ, Cornell HJ, Herington AC. Effects of free and bound insulin-like growth factors on proteoglycan metabolism in articular cartilage explants. J Orthop Res 1992;10:14-22.
14. D'Ercole AJ, Hill DJ, Strain AJ, Underwood LE. Tissue and plasma somatomedin-C/insulin-like growth factor I concentations in the human fetus during the first half of gestation. Pediatr Res 1986;20:253-5.
15. Han VK, D'Ercole AJ, Lund PK. Cellular localization of somatomedin (insulin-like growth factor) messenger RNA in the human fetus. Science 1987;236:193-7.
16. Schoenle E, Zapf J, Humbel RE, Froesch ER. Insulin-like growth factor I stimulates growth in hypophysectomized rats. Nature 1982;296:252-3.
17. Trippel SB, Corvol MT, Dumontier MF, Rappaport R, Hung HH, Mankin HJ. Effect of somatomedin-C/insulin-like growth factor I and growth hormone on cultured growth plate and articular chondrocytes. Pediatr Res 1989;25:76-82.
18. Bhaumick B. Insulin-like growth factor (IGF) binding proteins and insulin-like growth factor secretion by cultured chondrocyte cells: Identification, characterization and ontogeny during cell differentiation. Regul Pept 1993;48:113-22.
19. Bhaumick B, Bala RM. Differential effects of insulin-like growth factors I and II on growth, differentiation and glucoregulation in differentiating chondrocyte cells in culture. Acta Endocrinol 1991;125:201-11.
20. Holthuizen E, LeRoith D, Lund PK, Roberts CT Jr, Rotwein P, Spencer EM, et al. Modern concepts in insulin-like growth factors. New York: Elsevier, 1991:733-6.
21. Sara VR, Hall K. Insulin-like growth factors and their binding proteins. Physiol Rev 1990;70:591-614.
22. Czech MP. Signal transmission by the insulin-like growth factors. Cell 1989;59:235-8.
23. Kiess W, Blickenstaff GD, Sklar MM, Thomas CL, Nissley SP, Sahagian GG. Biochemical evidence that the type II insulin-like growth factor receptor is identical to the cation-dependent mannose 6-phosphate receptor. J Biol Chem 1988;263:9339-44.
24. Oshima A, Nolan CM, Kyle JW, Grubb JH, Sly WS. The human cation-independent mannose 6-phosphate receptor. Cloning and sequence of the full-length cDNA and expression of functional receptor in COS cells. J Biol Chem 1988;263:2553-62.
25. Schouten JSAG, Van den Ouweland FA, Valkenburg HA, Lamberts SW. Insulin-like growth factor-1: A prognostic factor of knee osteoarthritis. Br J Rheumatol 1993;32:274-80.
26. McAlindon TE, Teale D, Dieppe PA. Insulin-like growth factor 1: Effect of age acounts for apparent correlation with sclerosis and osteophytosis in osteoarthritis of the knee [abstract]. Br J Rheumatol 1992;31(Suppl 2):213.
27. Denko CW, Boja B, Moskowitz RW. Growth promoting peptides in osteoarthritis: insulin, insulin-like growth factor-I, growth hormone. J Rheumatol 1990;17:1217-21.
28. Hochberg MC, Lethbridge-Cejku M, Scott WW Jr, Reichle R, Plato CC, Tobin JD. Serum levels of insulin-like growth factor I in subjects with osteoarthritis of the knee. Data from the Baltimore Longitudinal Study of Aging. Arthritis Rheum 1994;37:1177-80.
29. Lloyd ME, Hart DJ, Nandra D, McAlindon TE, Wheeler M, Doyle DV, et al. Relation between insulin-like growth factor-I concentrations, osteoarthritis, bone density, and fractures in the general population: The Chingford study. Ann Rheum Dis 1996;55:870-4.
30. Denko CW, Boja B. Growth factors in asymptomatic osteoarthritis - insulin, insulin-like growth factor-1, growth hormone. Immunopharmacology 1993;2:71-6.
31. Schneiderman R, Rosenberg N, Hiss J, Lee P, Liu F, Hintz RL, et al. Concentration and size distribution of insulin-like growth factor-1 in human normal and osteoarthritic synovial fluid and cartilage. Arch Biochem Biophys 1995;1:173-88.
32. Tavera C, Abribat T, Reboul P, Doré S, Brazeau P, Pelletier JP, et al. IGF and IGF-binding protein system in the synovial fluid of osteoarthritc and rheumatoid arthritic patients. Osteoarthritis Cartilage 1996;4:263-74.
33. Fernihough JK, Billingham ME, Cwyfan-Hughes S, Holly JM. Local disruption of the insulin-like growth factor system in the arthritic joint. Arthritis Rheum 1996;39:1556-65.
34. Isaksson OGP, Ohlsson C, Nilsson A, Isgaard J, Lindahl A. Regulation of cartilage growth by growth hormone and insulin-like growth factor I. Pediatr Nephrol 1991;5:451-3.
35. Doré S, Abribat T, Rousseau N, Brazeau P, Tardif G, Di Battista JA, et al. Increased insulin-like growth factor 1 production by human osteoarthritic chondrocytes is not dependent on growth hormone action. Arthritis Rheum 1995;38:413-9.
36. Olney RC, Tsuchiya K, Wilson DM, Mohtai M, Maloney WJ, Schurman DJ, et al. Chondroyctes from osteoarthritic cartilage have increased expression of insulin-like growth factor I (IGF-1) and IGF-binding protein-3 (IGFBP-3) and -5, but not IGF-2 or IGFBP-4. J Clin Endocrinol Metab 1996;81:1096-103.
37. Middleton JF, Tyler JA. Upregulation of insulin-like growth factor-I gene expression in the lesions of osteoarthritic human articular cartilage. Ann Rheum Dis 1992;51:440-7.
38. Doré S, Pelletier JP, Di Battista JA, Tardif G, Brazeau P, Martel-Pelletier J. Human osteoarthritic chondrocytes possess an increased number of insulin-like growth factor 1 binding sites but are unresponsive to its stimulation. Possible role of IGF-1-binding proteins. Arthritis Rheum 1994;37:253-63.
39. Tardif G, Reboul P, Pelletier JP, Geng C, Cloutier JM, Martel-Pelletier J. Normal expression of type 1 insulin-like growth factor receptor by human osteoarthritic chondrocytes with increased expression and synthesis of insulin-like growth factor binding proteins. Arthritis Rheum 1996;39:968-78.
40. Verschure PJ, Van Marle J, Joosten LA, van den Berg WB. Histochemical analysis of insulin-like growth factor-1 binding sites in mouse normal and experimentally induced arthritic articular cartilage. Histochem J 1996;28:13-23.
41. Pelletier JP, Martel-Pelletier J. Evidence for the involvement of interleukin 1 in human osteoarthritic cartilage degradation: Protective effect of NSAID. J Rheumatol 1989;16:19-27.
42. Matsumoto T, Tsukazaki T, Enomoto H, Iwasaki K, Yamashita S. Effects of interleukin-1 beta on insulin-like growth factor-I autocrine/paracrine axis in cultured rat articular chondrocytes. Ann Rheum Dis 1994;53:128-33.
43. Linkhart TA, MacCharles DC. Interleukin-1 stimulates release of insulin like growth factor-I from neonatal mouse calvaria by a prostaglandin synthesis-dependent mechanism. Endocrinology 1992;131:2297-2305.
44. Olney RC, Wilson DM, Montai M, Fielder PJ, Smith RL. Interleukin-1 and tumor necrosis factor-alpha increase insulin-like growth factor-binding protein 3 (IGFBP-3) production and IGFBP-3 protease activity in human articular chondrocytes. J Endocrinol 1995;146:279-86.
45. Yateman ME, Claffey DC, Cwyfan Hughes SC, Frost VJ, Wass JA, Holly JMP. Cytokines modulate the sensitivity of human fibroblasts to stimulation with insulin-like growth factor-I (IGF-1) by altering endogenous IGF-binding protein production. J Endocrinol 1993;137:151-9.
46. Scharla SH, Strong DD, Mohan S, Chevalley T, Linkhart TA. Effect of tumor necrosis factor-alpha on the expression of insulin-like growth factor 1 and insulin-like growth factor binding protein 4 in mouse osteoblasts. Eur J Endocrinol 1994;131:293-301.
47. Laouar A, Wietzerbin J, Bauvois B. Protease catalyzed conversion of insulin-like growth factor-1 and interleukin-6 into high-molecular mass species through the sequential action of hematopoietic surface-associated cathepsin G and gamma-glutamyl transpeptidase-related activities. Eur J Biochem 1994;223:617-24.
48. Martel-Pelletier J, Faure MP, McCollum R, Mineau F, Cloutier JM, Pelletier JP. Plasmin, plasminogen activators and inhibitor in human osteoarthritic cartilage. J Rheumatol 1991;18:1863-71.
49. Martel-Pelletier J, Cloutier JM, Pelletier JP. Cathepsin B and cysteine protease inhibitors in human OA: Effect of intra-articular steroid injections. J Orthop Res 1990;8:336-44.
50. Isaksson OGP, Nilsson A, Isgaard J, Lindahl A. Cartilage as a target tissue for growth hormone and insulin-like growth factor I. Acta Paediatr Suppl 1990;367:137-41.
51. Isgaard J. Expression and regulation of IGF-1 in cartilage and skeletal muscle. 1992;2:16-22.
52. Barnard R, Haynes KM, Werther GA, Waters MJ. The ontogeny of growth hormone receptors in the rabbit tibia. Endocrinology 1988;122:2562-9.
53. Isaksson OGP, Lindahl A, Nilsson A, Isgaard J. Mechanism of the stimulatory effect of growth hormone on longitudinal bone growth. Endocr Rev 1987;8:426-38.
54. Elford PR, Lamberts SW. Contrasting modulation by transforming growth factor-beta-1 of insulin-like growth factor-I production in osteoblasts and chondrocytes. Endocrinology 1990;127:1635-9.
55. Jones KL, Villela JF, Lewis UJ. The growth of cultured rabbit articular chondrocytes is stimulated by pituitary growth factors by not by purified human growth hormone or bovine prolactin. Endocrinology 1986;118:2588-93.
56. Kasper S, Friesen HG. Human pituitary tissue secretes a potent growth factor for chondrocyte proliferation. J Clin Endocrinol Metab 1986;62:70-6.
57. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: Biological actions. Endocr Rev 1995;16:3-34.
58. Oh Y, Nagalla SR, Yamanaka Y, Kim HS, Wilson E, Rosenfeld RG. Synthesis and characterization of insulin-like growth factor binding protein (IGFBP)-7. Recombinant human mac25 protein specifically binds IGF-I and -II. J Biol Chem 1996;271:30322-5.
59. Wilson EM, Oh Y, Rosenfeld RG. Generation and characterization of an IGFBP-7 antibody: Identification of 31kD IGFBP-7 in human biological fluids and Hs578T human breast cancer conditioned media. J Clin Endocrinol Metab 1997;82:1301-3.
60. Rechler MM. Growth inhibition by insulin-like growth factor (IGF) binding protein-3 - what's IGF got to do with it? [editorial]. Endocrinology 1997;138:2645-7.
61. Lamson G, Giudice LC, Cohen P, Liu F, Gargosky S, Muller HL, et al. Proteolysis of IGFBP-3 may be a common regulatory mechanism of IGF action in vivo. Growth Regul 1993;3:91-5.
62. Cohen P, Graves HC, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 1992;75:1046-53.
63. Rosenfeld RG, Pham H, Cohen P, Fielder P, Gargosky SE, Muller H, et al. Insulin-like growth factor binding proteins and their regulation. Acta Paediatr Suppl 1994;399:154-8.
64. Olney RC, Smith RL, Kee Y, Wilson DM. Production and hormonal regulation of insulin-like growth factor binding proteins in bovine chondrocytes. Endocrinology 1993;133:563-70.
65. 2 up-regulates insulin-like growth factor binding-3 expression and synthesis in human articular chondrocytes by a cAMP-independent pathway: Role of calcium and protein kinase A and C. J Cell Biochem 1996;62:1-14.
66. Matsumoto T, Gargosky SE, Iwasaki K, Rosenfeld RG. Identification and characterization of insulin-like growth factors (IGFs), IGF-binding proteins (IGFBPs), and IGFBP proteases in human synovial fluid. J Clin Endocrinol Metab 1996;81:150-5.
67. Kanety H, Shimon I, Ehrenfeld M, Israeli A, Pariente C, Karasik A. Insulin-like growth Factor I and its binding proteins 3 and 4 are increased in Human inflammatory synovial fluid. J Rheumatol 1996;23:815-8.
68. Oh Y, Muller HL, Lamson G, Rosenfeld RG. Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition. J Biol Chem 1993;268:14964-71.
69. Oh Y, Muller HL, Pham H, Rosenfeld RG. Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells. J Biol Chem 1993; 268:26045-8.
70. Liu L, Delbe J, Blat C, Zapf J, Harel L. Insulin-like growth factor binding protein (IGFBP-3), an inhibitor of serum growth factors other than IGF-I and -II. J Cell Physiol 1992;153:15-21.
71. Valentinis B, Bhala A, DeAngelis T, Baserga R, Cohen P. The human insulin-like growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-1 receptor gene. Mol Endocrinol 1995;9:361-7.
72. De Mellow JS, Baxter RC. Growth hormone-dependent insulin-like growth factor (IGF) binding protein both inhibits and potentiates IGF-1-stimulated DNA synthesis in human skin fibroblasts. Biochem Biophys Res Commun 1988;156:199-204.
73. Rechler MM. Molecular endocrinology: Basic concepts and clinical correlations. New York: Raven Press Ltd., 1995:155-80.
74. Fowlkes JL, Serra DM, Rosenberg CK, Thrailkill KM. Insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) functions as an IGF-reversible inhibitor of IGFBP-4 proteolysis. J Biol Chem 1995;270:27481-8.
75. Donnelly MJ, Holly JM. The role of IGFBP-3 in the regulation of IGFBP-4 proteolysis. J Endocrinol 1996;149:R1-7.
76. Cubbage ML, Suwanichkul A, Powell DR. Insulin-like growth factor binding protein-3. Organisation of the human chromosomal gene and demonstration of promoter activity. J Biol Chem 1990;265:12642-9.
77. Duan C, Clemmons DR. Transcription factor AP-2 regulates human insulin-like growth factor binding protein-5 gene expression. J Biol Chem 1995;270:24844-51.
78. McCarthy TL, Casinghino S, Mittanck DW, Ji CH, Centrella M, Rotwein P. Promoter-dependent and -independent activation of insulin-like growth factor binding protein-5 gene expression by prostaglandin E2 in primary rat osteoblasts. J Biol Chem 1996;271:6666-71.
79. Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR, et al. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995;377:646-9.
80. Radulescu RT. Nuclear localization signal in insulin-like growth factor-binding protein type 3. Trends Biochem Sci 1994;19:278.
81. Radulescu RT, Wendtner CM. Proposed interaction between insulin and retinoblastoma protein. J Mol Recognit 1992;5:132-7.
82. Radulescu RT, Wendtner CM. Hormone and growth factor subunits: A novel perception of cell growth regulation. J Endocrinol 1993;139:1-7.
83. LaTour D, Mohan S, Linkhart TA, Baylink DJ, Strong DD. Inhibitory insulin-like growth factor-binding protein: cloning, complete sequence, and physiological regulation. Mol Endocrinol 1990;4:1806-14.
84. Dai B, Widen SG, Mifflin R, Singh P. Cloning of the functional promoter for human insulin-like growth factor binding protein-4 gene: endogenous regulation. Endocrinology 1997;138:332-3.
85. Gao L, Ling N, Shimasaki S. Structure of the rat insulin-like growth factor binding protein-4 gene. Biochem Biophys Res Commun 1993;190:1053-9.
86. Yang YW, Pioli P, Fiorelli G, Brandi ML, Rechler MM. Cyclic adenosine monophosphate stimulates insulin-like growth factor binding protein-4 and its messenger ribonucleic acid in a clonal endothelial cell line. Endocrinology 1993;133:343-51.
87. ++/-calmodulin regulated processes. J Cell Biochem 1997;65:408-19.
88. Conti M, Jin SL, Monaco L, Repaske DR, Swinnen JV. Hormonal regulation of cyclic nucleotide phosphodiesterases. Endocr Rev 1991;12:218-34.
89. Sette C, Iona S, Conti M. The short-term activation of a rolipram-sensitive, cAMP-specific phosphodiesterase by thyroid-stimulating hormone in thyroid FRTL-5 cells is mediated by a cAMP-dependent phosphorylation. J Biol Chem 1994;269:9245-52.
90. Schmid C, Ernst M. Insulin-like growth factors. In: Gowen M, editor. Cytokines and bone metabolism. Boca Raton: CRC Press, 1992:229-65.
91. Canalis E, McCarthy TL, Centrella M. The role of growth factors in skeletal remodeling. Endocrinol Metab Clin North Am 1989;18:903-18.
92. Mohan S, Buylink DJ. Bone growth factors. Clin Orthop 1991:30-48.
93. Mohan S, Buylink DJ. Modern concepts of insulin-like growth factors. New York: Elsevier, 1991:169-84.
94. Mohan S, Jennings JC, Linkhart TA, Baylink DJ. Primary structure of human skeletal growth factor: Homology with human insulin-like growth factor-II. Biochim Biophys Acta 1988;966:44-55.
95. Hock JM, Centrella M, Canalis E. Insulin-like growth factor I has independent effects on bone matrix formation and cell replication. Endocrinology 1988;122:254-60.
96. Ernst M, Froesch ER. Osteoblastlike cells in a serum-free methylcellulose medium form colonies: Effects of insulin and insulinlike growth factor I. Calcif Tissue Int 1987;40:27-34.
97. Canalis E. Insulin-like growth factors and osteoporosis. Bone 1997;21:215-6.
98. Canalis E, McCarthy TL, Centrella M. Effects of platelet-derived growth factor on bone formation in vitro. J Cell Physiol 1989;140:530-7.
99. Rosen CJ, Dimai HP, Vereault D, Donahue LR, Beamer WG, Farley J, et al. Circulating and skeletal insulin-like growth factor-I (IGF-1) concentrations in two inbred strains of mice with different bone mineral densities. Bone 1997;21:217-23.
100. Canalis E. Growth hormone, skeletal growth factors and osteoporosis. Endocrine Practice 1995;1:39-43.
101. McCarthy TL, Centrella M, Canalis E. Parathyroid hormone enhances the transcript and polypeptide levels of insulin-like growth factor I in osteoblast-enriched cultures from fetal rat bone. Endocrinology 1989;124:1247-53.
102. Isaksson OG, Jansson JO, Gause IA. Growth hormone stimulates longitudinal bone growth directly. Science 1982;216:1237-9.
103. Hansson HA, Nilsson A, Isgaard J, Billig H, Isaksson OGP, Skottner A, et al. Immunohistochemical localization of insulin-like growth factor I in the adult rat. Histochemistry 1988;89:403-10.
104. Luo JM, Murphy LJ. Dexamethasone inhibits growth hormone induction of insulin-like growth factor-I (IGF-1) messenger ribonucleic acid (mRNA) in hypophysectomized rats and reduces IGF-1 mRNA abundance in the intact rat. Endocrinology 1989;125:165-71.
105. 3 and activity on human osteoblast-like cells in short-term cultures. Bone 1990;11:81-6.
106. Linkhart TA, Mohan S. Parathyroid hormone stimulates release of insulin-like growth factor-I (IGF-1) and IGF-2 from neonatal mouse calvaria in organ culture. Endocrinology 1989;125:1484-91.
107. Rosen CJ, Donahue LR, Hunter SJ. Insulin-like growth factors and bone: the osteoporosis connection. Proc Soc Exp Biol Med 1994;206:83-102.
108. Pfeilschifter J, Lempart UG, Naumann A, Minne HW, Ziegler R. Transforming growth factor beta increases insulin-like growth factor I (IGFI) secretion in osteoblast-like cells. Acta Endocrinol 1989;120(Suppl 1):144-5.
109. Canalis E, Centrella M, Burch W, McCarthy TL. Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures. J Clin Invest 1989;83:60-5.
110. Schmid C, Ernst M, Zapf J, Froesch ER. Release of insulin-like growth factor carrier proteins by osteoblasts: Stimulation by estradiol and growth hormone. Biochem Biophys Res Commun 1989;160:788-94.
111. Benedict MR, Ayers DC, Calore JD, Richman RA. Differential distribution of insulin-like growth factors and their binding proteins within bone: Relationship to bone mineral density. J Bone Miner Res 1994;9:1803-11.
112. Bikle DD, Harris J, Halloran BP, Morey-Holton ER. Skeletal unloading induces resistance to insulin-like growth factor I. J Bone Miner Res 1994;9:1789-96.
113. Bennett A, Chen T, Feldman D, Hintz RL, Rosenfeld RG. Characterization of insulin-like growth factor I receptors on cultured rat bone cells: Regulation of receptor concentration by glucocorticoids. Endocrinology 1984;115:1577-83.
114. Centrella M, McCarthy TL, Canalis E. Receptors for insulin-like growth factors-I and -II in osteoblast-enriched cultures from fetal rat bone. Endocrinology 1990;126:39-44.
115. Slootweg MC, Hoogerbrugge CM, de Poorter TL, Duursma SA, van Buul-Offers SC. The presence of classical insulin-like growth factor (IGF) type-I and -II receptors on mouse osteoblasts: Autocrine/paracrine growth effect of IGFs? J Endocrinol 1990; 125:271-7.
116. Mohan S, Linkhart T, Rosenfeld R, Baylink D. Characterization of the receptor for insulin-like growth factor II in bone cells. J Cell Physiol 1989;140:169-76.
117. Centrella M, McCarthy TL, Canalis E. Beta 2-microglobulin enhances insulin-like growth factor I receptor levels and synthesis in bone cell cultures. J Biol Chem 1989;264:18268-71.
118. Campbell PG, Novak JF, Yanosick TB, McMaster JH. Involvement of the plasmin system in dissociation of the insulin-like growth factor-binding protein complex. Endocrinology 1992;130:1401-12.
119. Saksela O, Rifkin DB. Cell-associated plasminogen activation: Regulation and physiological functions. Annu Rev Cell Biol 1988;4:93-126.
120. Vassalli JD, Sappino AP, Belin D. The plasminogen activator/ plasmin system. J Clin Invest 1991;88:1067-72.
121. Koutsilieris M, Frenette G, Lazure C, Lehoux JG, Govindan MV, Polychronakos C. Urokinase-type plasminogen activator: A paracrine factor regulating the bioavailability of IGFs in PA-III cell-induced osteoblastic metastases. Anticancer Res 1993;13:481-6.
122. Martin TJ, Allan EH, Fukumoto S. The plasminogen activator and inhibitor system in bone remodeling. Growth Regul 1993;3:209-14.
123. Radin EL, Paul IL, Tolkoff MJ. Subchondral changes in patients with early degenerative joint disease. Arthritis Rheum 1970; 13:400-5.
124. Radin EL, Rose RM. Role of subchondral bone in the initiation and progression of cartilage damage. Clin Orthop 1986;213:34-40.
125. Wuster C, Blum WF, Schlemilch S, Ranke MB, Ziegler R. Decreased serum levels of insulin-like growth factors and IGF binding protein 3 in osteoporosis. J Intern Med 1993;234:249-55.
126. Hilal G, Martel-Pelletier J, Pelletier JP, Ranger, Lajeunesse D. Osteoblast-like cells from human subchondral ostoearthritic bone demonstrate an altered phenotype in vitro: Possible role in subchondral bone sclerosis. Arthritis Rheum 1997, in press.
127. Lalou C, Lassarre C, Binoux M. A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF- I and insulin. Endocrinology 1996;137:3206-12.
128. Saxne T, Lecander I, Geborek P. Plasminogen activators and plasminogen activator inhibitors in synovial fluid. Difference between inflammatory joint disorders and osteoarthritis. J Rheumatol 1993;20:91-6.
129. Murphy G, Cockett MI, Stephens PE, Smith BJ, Docherty AJ. Stromelysin is an activator of procollagenase. A study with natural and recombinant enzymes. Biochem J 1987;248:265-8.
130. Lyons RM, Gentry LE, Purchio AF, Moses HL. Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. J Cell Biol 1990;110:1361-7.
131. Sato Y, Rifkin DB. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: Activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture. J Cell Biol 1989;109:309-15.
132. Durham SK, Riggs BL, Conover CA. The insulin-like growth factor-binding protein-4 (IGFBP-4)-IGFBP-4 protease system in normal human osteoblast-like cells: Regulation by transforming growth factor-beta. J Clin Endocrinol Metab 1994;79:1752-8.
133. Dequeker J, Mohan R, Finkelman RD, Aerssens J, Baylink DJ. Generalized osteoarthritis associated with increased insulin-like growth factor types I and II and transforming growth factor beta in cortical bone from the iliac crest. Possible mechanism of increased bone density and protection against osteoporosis. Arthritis Rheum 1993;36:1702-8.
134. Rabbani SA, Desjardins J, Bell AW, Banville D, Mazar A, Henkin J, et al. An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells. Biochem Biophys Res Commun 1990; 173:1058-64.
135. Allan EH, Martin TJ. The plasminogen activator inhibitor system in bone cell function. Clin Orthop 1995;313:54-63.